Literature DB >> 21884014

Novel treatments for cardiovascular disease prevention.

Mark D Huffman1, Deepak Bhatnagar.   

Abstract

The purpose of this review is to describe novel pharmacologic and nonpharmacologic preventive therapies, as well as new strategies to improve delivery of available therapies. Cardiovascular disease (CVD) is the leading cause of death worldwide, and prevention plays a critical role in curbing the global epidemic. Despite available treatment for tobacco addiction, platelet inhibition, blood pressure, and lipid lowering for reduction of atherosclerotic disease, significant gaps in treatment of total CVD remain. We review a range of new preventive treatment options, including drugs for tobacco cessation, platelet/thrombotic inhibition, lipid- and blood pressure-lowering; nonpharmacologic options such as left atrial appendage closure devices and caloric restriction; and strategies such as fixed-dose combination drugs, laboratory screening for drug tailoring, and community-based prevention programs. CVD preventive research continues to evolve and provide clinicians and patients with novel pharmacologic and nonpharmacologic therapies, including new preventive strategies.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21884014      PMCID: PMC3911909          DOI: 10.1111/j.1755-5922.2011.00280.x

Source DB:  PubMed          Journal:  Cardiovasc Ther        ISSN: 1755-5914            Impact factor:   3.023


  46 in total

Review 1.  By Jove! What is a clinician to make of JUPITER?

Authors:  Sanjay Kaul; Ryan P Morrissey; George A Diamond
Journal:  Arch Intern Med       Date:  2010-06-28

2.  The polypill and cardiovascular disease.

Authors:  Tom Fahey; Peter Brindle; Shah Ebrahim
Journal:  BMJ       Date:  2005-05-07

3.  Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.

Authors:  S Yusuf; P Pais; R Afzal; D Xavier; K Teo; J Eikelboom; A Sigamani; V Mohan; R Gupta; N Thomas
Journal:  Lancet       Date:  2009-03-30       Impact factor: 79.321

4.  Prasugrel in clinical practice.

Authors:  Deepak L Bhatt
Journal:  N Engl J Med       Date:  2009-07-15       Impact factor: 91.245

5.  Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development.

Authors:  Robert L Wilensky; Yi Shi; Emile R Mohler; Damir Hamamdzic; Mark E Burgert; Jun Li; Anthony Postle; Robert S Fenning; James G Bollinger; Bryan E Hoffman; Daniel J Pelchovitz; Jisheng Yang; Rosanna C Mirabile; Christine L Webb; LeFeng Zhang; Ping Zhang; Michael H Gelb; Max C Walker; Andrew Zalewski; Colin H Macphee
Journal:  Nat Med       Date:  2008-09-21       Impact factor: 53.440

Review 6.  Phospholipase A2s: developing drug targets for atherosclerosis.

Authors:  Keith Suckling
Journal:  Atherosclerosis       Date:  2010-03-16       Impact factor: 5.162

7.  Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis.

Authors:  Matthew R Weir; Christopher Bush; David R Anderson; Jack Zhang; Deborah Keefe; Andrew Satlin
Journal:  J Am Soc Hypertens       Date:  2007 Jul-Aug

8.  Aliskiren combined with losartan in type 2 diabetes and nephropathy.

Authors:  Hans-Henrik Parving; Frederik Persson; Julia B Lewis; Edmund J Lewis; Norman K Hollenberg
Journal:  N Engl J Med       Date:  2008-06-05       Impact factor: 91.245

Review 9.  Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases.

Authors:  John D Imig; Bruce D Hammock
Journal:  Nat Rev Drug Discov       Date:  2009-10       Impact factor: 84.694

10.  Intravenous platelet blockade with cangrelor during PCI.

Authors:  Deepak L Bhatt; A Michael Lincoff; C Michael Gibson; Gregg W Stone; Steven McNulty; Gilles Montalescot; Neal S Kleiman; Shaun G Goodman; Harvey D White; Kenneth W Mahaffey; Charles V Pollack; Steven V Manoukian; Petr Widimsky; Derek P Chew; Fernando Cura; Ivan Manukov; Frantisek Tousek; M Zubair Jafar; Jaspal Arneja; Simona Skerjanec; Robert A Harrington
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

View more
  3 in total

Review 1.  Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases.

Authors:  Ehete Bahiru; Angharad N de Cates; Matthew Rb Farr; Morag C Jarvis; Mohan Palla; Karen Rees; Shah Ebrahim; Mark D Huffman
Journal:  Cochrane Database Syst Rev       Date:  2017-03-06

Review 2.  Current research trends and challenges in tissue engineering for mending broken hearts.

Authors:  Muhammad Qasim; Pala Arunkumar; Heather M Powell; Mahmood Khan
Journal:  Life Sci       Date:  2019-05-17       Impact factor: 5.037

Review 3.  Chitosan as Functional Biomaterial for Designing Delivery Systems in Cardiac Therapies.

Authors:  Bhaumik Patel; Ravi Manne; Devang B Patel; Shashank Gorityala; Arunkumar Palaniappan; Mallesh Kurakula
Journal:  Gels       Date:  2021-12-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.